PD-L1 × TIGIT × LAG3 format enables simultaneous interrogation of three complementary checkpoint pathways within a single in ...
Risk of non-small cell lung cancer (NSCLC), a malignancy that develops in the tissues of the lung, increases considerably ...
Circulating tumor DNA and its correlation with survival in hormone receptor positive HER2-negative stages I-III breast cancer: A systematic review. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Mechanistic insights into how B7x-mediated immune evasion drives resistance to PD-1/PD-L1 blockade in bladder cancer ...
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...
Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the tumor site for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results